SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL CFTR POTENTIATOR GLPG1837 IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Vanhoutte, F. P. [1 ]
Gouy, M. [2 ]
Haazen, W. [3 ]
Kanters, D. [1 ]
De Beckker, G. [1 ]
Geller, D. E. [4 ]
Van de Wal, K. [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
[2] Galapagos SASU, Romainville, France
[3] SGS CPU, Antwerp, Belgium
[4] AbbVie, N Chicago, IL USA
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
258
引用
收藏
页码：289 / 289
页数：1
相关论文
共 50 条
  • [1] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL CFTR POTENTIATOR GLPG3067 IN HEALTHY VOLUNTEERS
    Petkova, M.
    Gesson, C.
    Notebaert, S.
    Conrath, K.
    Corveleyn, S.
    Geller, D.
    Van de Steen, O.
    De Kock, H.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S227 - S227
  • [2] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF CFTR POTENTIATOR GLPG2451 WITH AND WITHOUT CFTR CORRECTOR GLPG2222 IN HEALTHY VOLUNTEERS
    van't Klooster, G. A.
    Brearley, C.
    Gesson, C.
    Kanters, D.
    Conrath, K.
    Corveleyn, S.
    Van de Steen, O.
    De Kock, H.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S314 - S314
  • [3] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL CFTR CORRECTOR MOLECULE GLPG2222 IN HEALTHY VOLUNTEERS
    Van de Steen, O.
    Namour, F.
    Kanters, D.
    Geller, D. E.
    de Kock, H.
    Vanhoutte, F. P.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 287 - 287
  • [4] THE NOVEL POTENTIATOR GLPG1837 MODULATES CFTR THROUGH DIFFERENT MODE OF ACTION THAN IVACAFTOR (KALYDECO)
    Peters, F.
    Mijnders, M.
    Andrews, M.
    Van der Plas, S.
    Conrath, K.
    Braakman, I
    Kleizen, B.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 195 - 195
  • [5] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES OF GLPG2737, A NOVEL CFTR CORRECTOR MOLECULE, IN HEALTHY VOLUNTEERS
    Brearley, C.
    Gesson, C.
    Kanters, D.
    Conrath, K.
    Corveleyn, S.
    Geller, D.
    De Kock, H.
    Van de Steen, O.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S313 - S313
  • [6] CFTR POTENTIATOR FDL176: SAFETY, TOLERABILITY AND PHARMACOKINETICS
    Ordonez, C.
    Burr, L.
    Mulrennan, S.
    Chai, J.
    Kolodziej, A.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 246 - 247
  • [7] Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
    Yeh, Han-, I
    Qiu, Liming
    Sohma, Yoshiro
    Conrath, Katja
    Zou, Xiaoqin
    Hwang, Tzyh-Chang
    JOURNAL OF GENERAL PHYSIOLOGY, 2019, 151 (07): : 912 - 928
  • [8] Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers
    Miceli, JJ
    Wilner, KD
    Swan, SK
    Tensfeldt, TG
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (06): : 620 - 630
  • [9] Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers
    Kanefendt, Friederike
    Thuss, Uwe
    Becka, Michael
    Boxnick, Stefanie
    Berse, Matthias
    Schultz, Armin
    Otto, Christiane
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 467 - 479
  • [10] Safety, tolerability and pharmacokinetics of SMP-114 (a novel candidate DMARD) in healthy volunteers
    Gaskin, C
    Taylor, M
    Tagashira, R
    Takada, Y
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 179 - 180
12345